• About Us
  • Contact Us
  • Cookie policy (EU)
  • Home
  • Privacy Policy
  • Video
  • Write for us
Today Headline
  • HOME
  • NEWS
    • POLITICS
    • News for today
    • Borisov news
  • FINANCE
    • Business
    • Insurance
  • Video
  • TECHNOLOGY
  • ENTERPRISE
  • LIFESTYLE
    • TRAVEL
    • HEALTH
    • ENTERTAINMENT
  • AUTOMOTIVE
  • SPORTS
  • Travel and Tourism
  • HOME
  • NEWS
    • POLITICS
    • News for today
    • Borisov news
  • FINANCE
    • Business
    • Insurance
  • Video
  • TECHNOLOGY
  • ENTERPRISE
  • LIFESTYLE
    • TRAVEL
    • HEALTH
    • ENTERTAINMENT
  • AUTOMOTIVE
  • SPORTS
  • Travel and Tourism
No Result
View All Result
TodayHeadline
No Result
View All Result

Tenon Medical Aims For $20 Million IPO For Commercialization Ramp

April 12, 2022
in Business
0
Tenon Medical Aims For $20 Million IPO For Commercialization Ramp
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter


Physical therapist fixing sacroiliac joint pain with IASTM guasha tool

marinesea/iStock via Getty Images

A Quick Take On Tenon Medical

Tenon Medical (TNON) has filed to raise $20 million in an IPO of its common stock, according to an S-1/A registration statement.

The firm is developing a medical device treatment for sacroiliac joint pain.

TNON management has proposed IPO pricing that is quite high – effectively pricing the IPO for perfection.

I’m on Hold for TNON due to excessive price expectations by management.

Company & Technology

Los Gatos, California-based Tenon was founded to develop its Catamaran SIJ Fusion System of instruments and implants to address the pain associated with sacroiliac joint disease.

Management is headed by president and CEO Steven M. Foster, who was previously Global Commercialization President of Safe Orthopedics SAS related to a surgical kit for lumbar spine fusion.

Tenon has booked fair market value investment of $13.7 million as of December 31, 2021 from investors including Zuhlke Ventures AG, TCTUG, SpineSource, WS Investment, K&A Investment and others.

Tenon – Customer Acquisition

The firm has received FDA marketing clearance (510[k]) for its surgical implant system and is preparing a national launch.

TNON will sell its products through a distributor go-to-market model. This presents advantages of quick launch and a simplified organization but the disadvantage of not controlling the firm’s own direct sales force for potentially more effective sales efforts and tighter customer relationships.

Sales and Marketing expenses as a percentage of total revenue have risen sharply as revenues have increased only slightly, as the figures below indicate:

Sales & Marketing

Expenses vs. Revenue

Period

Percentage

2021

1339.6%

2020

66.9%

(Source)

The Sales and Marketing efficiency multiple, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 0.1x in the most recent reporting period. (Source)

Tenon’s Market & Competition

According to a 2021 market research report by Verified Market Research, the global market for chronic lower back pain treatment was an estimated $6.3 billion in 2018 and is forecast to reach nearly $9.3 billion by 2026.

This represents a forecast CAGR of almost 5% from 2019 to 2026.

The main drivers for this expected growth are an increase in the number of nerve pain cases due to a significant rise in geriatric populations as the world’s population ages.

Also, there are five categories of lower back pain types:

  • Diskogenic Pain

  • Lumbar Spinal Stenosis

  • Sacroiliac Pain

  • Facet-Joint Pain

  • Others

Major competitive or other industry participants include:

  • Johnson & Johnson

  • Pfizer

  • Sanofi

  • Endo Pharmaceuticals

  • Merck

  • Vertebral Technologies

  • Medtronic

  • Boston Scientific

  • Bio Wave

  • Royal Philips

  • SI-Bone

Tenon Medical Financial Performance

The company’s recent financial results can be summarized as follows:

  • Growing topline revenue from a tiny base

  • Increasing gross profit and gross margin

  • High operating losses

  • Significant cash used in operations

Below are relevant financial results derived from the firm’s registration statement:

Total Revenue

Period

Total Revenue

% Variance vs. Prior

2021

$ 159,800

264.7%

2020

$ 43,820

Gross Profit (Loss)

Period

Gross Profit (Loss)

% Variance vs. Prior

2021

$ 105,028

310.9%

2020

$ 25,563

Gross Margin

Period

Gross Margin

2021

65.72%

2020

58.34%

Operating Profit (Loss)

Period

Operating Profit (Loss)

Operating Margin

2021

$ (6,460,722)

-4043.0%

2020

$ (536,289)

-1223.8%

Net Income (Loss)

Period

Net Income (Loss)

Net Margin

2021

$ (7,048,398)

-4410.8%

2020

$ (585,178)

-366.2%

Cash Flow From Operations

Period

Cash Flow From Operations

2021

$ (4,292,564)

2020

$ (167,363)

(Glossary Of Terms)

(Source)

As of December 31, 2021, Tenon had $916,677 in cash and $16.2 million in total liabilities.

Free cash flow during the twelve months ended December 31, 2021, was negative ($4.4 million).

Tenon Medical IPO Details

Tenon intends to raise $20 million in gross proceeds from an IPO of its common stock, offering 4 million shares at a proposed midpoint price of $5.00 per share.

No existing shareholders have indicated an interest to purchase shares at the IPO price.

Assuming a successful IPO, the company’s enterprise value at IPO would approximate $35.7 million, excluding the effects of underwriter over-allotment options.

The float to outstanding shares ratio (excluding underwriter over-allotments) will be approximately 33.16%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.

Management says it will use the net proceeds from the IPO as follows:

Proposed Use Of Proceeds

Proposed Use Of Proceeds (SEC EDGAR)

(Source)

Management’s presentation of the company roadshow is not available.

Regarding outstanding legal proceedings, the firm is being sued by a previous CEO for unpaid wages and other claims totaling $3.3 million plus attorneys’ fees and other costs, while management believes the claim should be limited to $600,000. Management provided no characterization of the potential outcome of the matter.

The listed bookrunners of the IPO are The Benchmark Company and Valuable Capital Limited.

Valuation Metrics For Tenon

Below is a table of relevant capitalization and valuation figures for the company:

Measure [TTM]

Amount

Market Capitalization at IPO

$60,305,960

Enterprise Value

$35,732,276

Price / Sales

377.38

EV / Revenue

223.61

EV / EBITDA

-5.53

Earnings Per Share

-$0.56

Operating Margin

-4043.01%

Net Margin

-4410.76%

Float To Outstanding Shares Ratio

33.16%

Proposed IPO Midpoint Price per Share

$5.00

Net Free Cash Flow

-$4,394,976

Free Cash Flow Yield Per Share

-7.29%

Debt / EBITDA Multiple

0.00

Revenue Growth Rate

264.67%

(Glossary Of Terms)

(Source)

Commentary About Tenon’s IPO

TNON is seeking U.S. public capital market funding for its continued commercialization and R&D efforts.

The company’s financials have produced increasing topline revenue from a tiny base, growing gross profit and gross margin, much higher operating losses and large cash used in operations.

Free cash flow for the twelve months ended December 31, 2021, was negative ($4.4 million).

Sales and Marketing expenses as a percentage of total revenue have risen sharply as revenue has grown only slightly; its Sales and Marketing efficiency multiple was 0.1x in 2021.

The firm currently plans to pay no dividends on its shares and anticipates that it will use any future earnings to reinvest back into the company’s growth efforts.

The market opportunity for treating lower back pain is large and expected to grow at a moderate rate of growth, while it features significant major players as competitors.

The Benchmark Company is the lead underwriter and IPOs led by the firm over the last 12-month period have generated an average return of negative (29.6%) since their IPO. This is a lower-tier performance for all major underwriters during the period.

The primary risk to the company’s stock is that it will likely need additional capital to continue its plans, so unless it produces significant upside catalysts, the stock may be diluted if equity capital is subscribed.

As for valuation, the IPO appears to be priced for perfection, with a proposed EV/Revenue of nearly 224x.

Given the pricey nature of the IPO, I’m on Hold for it.

Expected IPO Pricing Date: To be announced.

Tags: aimsCommercializationIPOmedicalmillionramptenon
Previous Post

Matildas leave it late to defeat Ferns

Next Post

A lackluster show not fit for Broadway

Related Posts

iPath Bloomberg Commodity Index Total Return ETN Update (NYSEARCA:DJP)
Business

iPath Bloomberg Commodity Index Total Return ETN Update (NYSEARCA:DJP)

peshkov/iStock via Getty Images Introduction...

Read more
Unfair TfL ULEZ charges: Private number plate triggers mistake
Business

Unfair TfL ULEZ charges: Private number plate triggers mistake

A business owner has been...

Read more
Business

Cash in on cashback: shop around for the best deals | Money

With many finances so tight,...

Read more
Gold ends at a nearly 2-week low as hints of progress in Russia-Ukraine talks crimp haven demand
Business

Gold books 3-day winning streak after notching first weekly gain in a month

Gold futures closed modestly higher...

Read more
Pitney Bowes: Upside Potential Thanks To Digital Innovation (NYSE:PBI)
Business

Pitney Bowes: Upside Potential Thanks To Digital Innovation (NYSE:PBI)

metamorworks/iStock via Getty Images Pitney...

Read more
Load More
Next Post
A lackluster show not fit for Broadway

A lackluster show not fit for Broadway

  • Trending
  • Comments
  • Latest
Thousands of Deaths and Adverse Reactions Deleted From VAERS – The Epoch Times

Thousands of Deaths and Adverse Reactions Deleted From VAERS – The Epoch Times

Sex/Life fans notice a HUGE editing fail in Adam Demos’ nude shower scene –

Sex/Life fans notice a HUGE editing fail in Adam Demos’ nude shower scene –

Horror as goat gives birth to ‘humanoid kid’ with baby-like face

Ex-porn star Lana Rhoades flaunts 2.5st weight loss two weeks after giving birth

Ex-porn star Lana Rhoades flaunts 2.5st weight loss two weeks after giving birth

19 children, 2 adults killed in Texas school rampage – The Associated Press

19 children, 2 adults killed in Texas school rampage – The Associated Press

Nancy Brophy, romance novelist who wrote “How to Murder Your Husband,” found guilty of murder 4 years after chef spouse found dead in kitchen – CBS News

Nancy Brophy, romance novelist who wrote “How to Murder Your Husband,” found guilty of murder 4 years after chef spouse found dead in kitchen – CBS News

Wall Street rallies as Fed minutes meet expectations – Reuters.com

Wall Street rallies as Fed minutes meet expectations – Reuters.com

Boeings Starliner capsule lands, completing a crucial step toward carrying NASA astronauts – CNBC

Boeings Starliner capsule lands, completing a crucial step toward carrying NASA astronauts – CNBC

About Us

Todayheadline the independent news and topics discovery
A home-grown and independent news and topic aggregation . displays breaking news linking to news websites all around the world.

Follow Us

Latest News

19 children, 2 adults killed in Texas school rampage – The Associated Press

19 children, 2 adults killed in Texas school rampage – The Associated Press

Nancy Brophy, romance novelist who wrote “How to Murder Your Husband,” found guilty of murder 4 years after chef spouse found dead in kitchen – CBS News

Nancy Brophy, romance novelist who wrote “How to Murder Your Husband,” found guilty of murder 4 years after chef spouse found dead in kitchen – CBS News

19 children, 2 adults killed in Texas school rampage – The Associated Press

19 children, 2 adults killed in Texas school rampage – The Associated Press

Nancy Brophy, romance novelist who wrote “How to Murder Your Husband,” found guilty of murder 4 years after chef spouse found dead in kitchen – CBS News

Nancy Brophy, romance novelist who wrote “How to Murder Your Husband,” found guilty of murder 4 years after chef spouse found dead in kitchen – CBS News

Wall Street rallies as Fed minutes meet expectations – Reuters.com

Wall Street rallies as Fed minutes meet expectations – Reuters.com

  • Real Estate
  • Education
  • Parenting
  • Cooking
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2021 All rights are reserved Todayheadline

No Result
View All Result
  • Real Estate
  • Education
  • Parenting
  • Cooking
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2021 All rights are reserved Todayheadline

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Posting....